Advances in directed protein evolution by recursive genetic recombination: Applications to therapeutic proteins

Current Opinion in Biotechnology

Volumn 12, Issue 4, 2001, Pages 361-370

  Kurtzman, Aaron L ^a   Govindarajan, Sridhar ^a   Vahle, Katherine ^a   Jones, Jennifer T ^a   Heinrichs, Volker ^a   Patten, Phillip A ^a  

^a MAXYGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN;

AGRICULTURE; BIODIVERSITY; BIOTECHNOLOGY; CHEMICAL ENGINEERING; GENE MUTATION; GENETIC ENGINEERING; GENETIC RECOMBINATION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; REVIEW; ROBOTICS; SCREENING;

ANTIBODIES; CYTOKINES; DIRECTED MOLECULAR EVOLUTION; MUTAGENESIS; PROTEIN ENGINEERING; PROTEINS; RECOMBINATION, GENETIC; VARIATION (GENETICS);

EID: 0035424404     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00228-7     Document Type: Review

References (66)

1. Rapid evolution of a protein in vitro by DNA shuffling
2. DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution
3. DNA shuffling of a family of genes from diverse species accelerates directed evolution
4. When blind is better: Protein design by evolution
5. Evolution of a cytokine using DNA family shuffling
6. Tuning the activity of an enzyme for unusual environments: Sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide
7. Directed evolution of subtilisin E in Bacillus subtilis to enhance total activity in aqueous dimethylformamide
8. The relation of recombination to mutational advance
9. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries
10. Directed evolution of proteins by exon shuffling
11. DNA shuffling method for generating highly recombined genes and evolved enzymes
12. Molecular evolution by staggered extension process (StEP) in vitro recombination
13. High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast: Statistical and functional analysis of a combinatorial library between human cytochrome P450 1A1 and 1A2
14. Protein engineering by cDNA recombination in yeasts: Shuffling of mammalian cytochrome P-450 functions
15. Recombination between similar but not identical DNA sequences during yeast transformation occurs within short stretches of identity
16. An effective family shuffling method using single-stranded DNA
17. Libraries of hybrid proteins from distantly related sequences
18. Rapid generation of incremental truncation libraries for protein engineering using α-phosphothioate nucleotides
19. A combinatorial approach to hybrid enzymes independent of DNA homology
20. Homology-independent protein engineering
21. Improved green fluorescent protein by molecular evolution using DNA shuffling
22. Tailoring in vitro evolution for protein affinity or stability
23. Molecular breeding of carotenoid biosynthetic pathways
24. Directed molecular evolution of cytochrome c peroxidase
25. Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling
26. DNA shuffling of subgenomic sequences of subtilisin
27. Directed evolution of ampicillin-resistant activity from a functionally unrelated DNA fragment: A laboratory model of molecular evolution
28. The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon
29. Side-effects of α-interferon in chronic hepatitis C
30. Monoclonal antibodies: A 25-year roller coaster ride: Recent FDA approvals for cancer therapies revitalize research
31. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
32. Affinity dependence of the B-cell response to antigen: A threshold, a ceiling, and the importance of off-rate
33. Kinetic and affinity limits on antibodies produced during immune responses
34. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display
35. Yeast surface display for screening combinatorial polypeptide libraries
36. Improving the tumor specificity and retention of antibody-based molecules
37. Antigen specificity and tumour targeting efficiency of a human carcinoembryonic antigen-specific scFv and affinity-matured derivatives
38. Structure of PAI-1 and its function in fibrinolysis: An update
39. Optimization of DNA shuffling for high fidelity recombination
40. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation
41. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene
42. Molecular breeding of viruses
43. Breeding of retroviruses by DNA shuffling for improved stability and processing yields
44. A RACHITT for our toolbox
45. Site-specific mutagenesis of the human fibroblast interferon gene
46. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The immunomedics study group
47. Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA
48. Enzyme therapy for Gaucher disease: The first 5 years
49. Production of soluble CD34 by human myeloid cells
50. Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor
51. Humanization of an anti-p185HER2 antibody for human cancer therapy
52. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I
53. Consensus interferon: A novel interferon for the treatment of hepatitis C
54. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
55. Production of recombinant human colony stimulating factors in yeast
56. Humanized antibodies as potential therapeutic drugs
57. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: Comparison with CT
58. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2
59. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ
60. The development of hirudin as an antithrombotic drug
61. New antiplatelet agents: Platelet GPIIb/IIIa antagonists
62. Interferon-α 2 variants in the human genome